Literature DB >> 17979965

Predictive validity of DSM-IV and ICD-10 criteria for ADHD and hyperkinetic disorder.

Soyoung I Lee1, Russell J Schachar, Shirley X Chen, Tisha J Ornstein, Alice Charach, Cathy Barr, Abel Ickowicz.   

Abstract

BACKGROUND: The goal of this study was to compare the predictive validity of the two main diagnostic schemata for childhood hyperactivity - attention-deficit hyperactivity disorder (ADHD; Diagnostic and Statistical Manual- IV) and hyperkinetic disorder (HKD; International Classification of Diseases- 10th Edition).
METHODS: Diagnostic criteria for ADHD and HKD were used to classify 419 children ages 6 to 16 years referred to a clinic for behavioral problems into one of four groups: HKD, ADHD combined subtype (ADHD-C), ADHD hyperactive-impulsive subtype (ADHD-HI), ADHD inattentive subtype (ADHD-IA). These groups were compared on clinical characteristics including total symptom severity, overall impairment, exposure to psychosocial and neuro-developmental risks, family history of ADHD in first-degree family members, rate and type of comorbidity, intelligence, academic achievement, and on laboratory tests of motor response inhibition and working memory with each other and with normal controls (47).
RESULTS: Of the 419 cases, there were 46 HKD (11.0%), 200 ADHD-C (47.7%), 60 ADHD-HI (14.3%) and 113 ADHD-IA (27.0%) cases. The HKD group had more symptoms and was more impaired on teachers' ratings than were the other groups. The ADHD-C and HKD groups had poorer inhibitory control than the ADHD-IA, ADHD-HI and control groups, and all four clinic groups showed inhibition deficit compared to controls. Groups did not differ in working memory. Compared to controls, the HKD, ADHD-C, ADHD-HI and ADHD-IA groups had higher familial risk of ADHD, greater psychosocial risk exposure, lower intellectual level and poorer academic attainment. However, we observed no differences among the clinic groups in these characteristics.
CONCLUSIONS: Like earlier versions, ICD-10 and DSM-IV continue to delineate diagnostic entities with substantially different prevalence in clinic samples. However, HKD, ADHD-C, ADHD-IA and ADHD-HI groups overlap substantially in terms of important clinical characteristics, although HKD and ADHD-C may be somewhat more severe variants of the condition than ADHD-IA and ADHD-HI.

Entities:  

Mesh:

Year:  2007        PMID: 17979965     DOI: 10.1111/j.1469-7610.2007.01784.x

Source DB:  PubMed          Journal:  J Child Psychol Psychiatry        ISSN: 0021-9630            Impact factor:   8.982


  17 in total

1.  Symptoms of attention-deficit/hyperactivity disorder in long-term survivors of childhood leukemia.

Authors:  Kevin R Krull; Raja B Khan; Kirsten K Ness; Davonna Ledet; Liang Zhu; Ching-Hon Pui; Scott C Howard; Deo Kumar Srivastava; Noah D Sabin; Melissa M Hudson; E Brannon Morris
Journal:  Pediatr Blood Cancer       Date:  2011-01-28       Impact factor: 3.167

2.  Family income in early childhood and subsequent attention deficit/hyperactivity disorder: a quasi-experimental study.

Authors:  Henrik Larsson; Amir Sariaslan; Niklas Långström; Brian D'Onofrio; Paul Lichtenstein
Journal:  J Child Psychol Psychiatry       Date:  2013-09-23       Impact factor: 8.982

3.  Pre-conceptual and prenatal supplementary folic acid and multivitamin intake, behavioral problems, and hyperkinetic disorders: A study based on the Danish National Birth Cohort (DNBC).

Authors:  Jasveer Virk; Zeyan Liew; Jørn Olsen; Ellen A Nohr; Janet M Catov; Beate Ritz
Journal:  Nutr Neurosci       Date:  2017-03-09       Impact factor: 4.994

4.  Maternal pre-pregnancy body mass index and offspring attention deficit hyperactivity disorder: a population-based cohort study using a sibling-comparison design.

Authors:  Qi Chen; Arvid Sjölander; Niklas Långström; Alina Rodriguez; Eva Serlachius; Brian M D'Onofrio; Paul Lichtenstein; Henrik Larsson
Journal:  Int J Epidemiol       Date:  2013-09-20       Impact factor: 7.196

Review 5.  Bipolar disorder and ADHD: comorbidity and diagnostic distinctions.

Authors:  Ciro Marangoni; Lavinia De Chiara; Gianni L Faedda
Journal:  Curr Psychiatry Rep       Date:  2015-08       Impact factor: 5.285

6.  ADHD latent class clusters: DSM-IV subtypes and comorbidity.

Authors:  Josephine Elia; Mauricio Arcos-Burgos; Kelly L Bolton; Paul J Ambrosini; Wade Berrettini; Maximilian Muenke
Journal:  Psychiatry Res       Date:  2009-11-08       Impact factor: 3.222

Review 7.  European consensus statement on diagnosis and treatment of adult ADHD: The European Network Adult ADHD.

Authors:  Sandra J J Kooij; Susanne Bejerot; Andrew Blackwell; Herve Caci; Miquel Casas-Brugué; Pieter J Carpentier; Dan Edvinsson; John Fayyad; Karin Foeken; Michael Fitzgerald; Veronique Gaillac; Ylva Ginsberg; Chantal Henry; Johanna Krause; Michael B Lensing; Iris Manor; Helmut Niederhofer; Carlos Nunes-Filipe; Martin D Ohlmeier; Pierre Oswald; Stefano Pallanti; Artemios Pehlivanidis; Josep A Ramos-Quiroga; Maria Rastam; Doris Ryffel-Rawak; Steven Stes; Philip Asherson
Journal:  BMC Psychiatry       Date:  2010-09-03       Impact factor: 3.630

Review 8.  A systematic review of combination therapy with stimulants and atomoxetine for attention-deficit/hyperactivity disorder, including patient characteristics, treatment strategies, effectiveness, and tolerability.

Authors:  Tamás Treuer; Susan Shur-Fen Gau; Luis Méndez; William Montgomery; Julie A Monk; Murat Altin; Shenghu Wu; Chaucer C H Lin; Héctor J Dueñas
Journal:  J Child Adolesc Psychopharmacol       Date:  2013-04-06       Impact factor: 2.576

9.  Comparison of the predictive validity of hyperkinetic disorder and attention deficit hyperactivity disorder.

Authors:  Russell Schachar; Shirley Chen; Jennifer Crosbie; Lisa Goos; Abel Ickowicz; Alice Charach
Journal:  J Can Acad Child Adolesc Psychiatry       Date:  2007-05

10.  Oculomotor anomalies in attention-deficit/hyperactivity disorder: evidence for deficits in response preparation and inhibition.

Authors:  E Mark Mahone; Stewart H Mostofsky; Adrian G Lasker; David Zee; Martha B Denckla
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2009-07       Impact factor: 8.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.